This profile has not been claimed and data may not be accurate.
13th percentile
Bristol Myers Squibb EVP and Chief Research Officer driving AI-powered drug discovery
Credibility
Domain Expertise · 67th percentile
- Deep research credibility: h-index 44, 27,269 citations (OpenAlex).
- Identified researcher with an h-index of 44 and 27,269 citations across 114 works (OpenAlex).
Relationship Matrix
Most Complimentary
Founder score
- 95%Probability of being accurate (95%)bms.com ranks #6,681 on the Majestic Million (global domain prominence).
- 92%Probability of being accurate (92%)Deep research credibility: h-index 44, 27,269 citations (OpenAlex).
- 92%Probability of being accurate (92%)Identified researcher with an h-index of 44 and 27,269 citations across 114 works (OpenAlex).
What you likely need
You're a rare operator-scientist with the credibility to shape how the industry thinks about AI-driven drug discovery, and the right rooms can accelerate that influence fast. The highest-leverage events for you are intimate dinners and roundtables where you're trading ideas with biotech founders, AI-bio investors, and fellow CROs — not presenting to a crowd. Think less conference panel, more closed-door session where your causal human biology framework becomes the intellectual anchor for a room of people who can act on it.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- positioningA closed-door roundtable dinner with CROs and CSOs from Flagship Pioneering, a16z Bio, and ARCH Venture-backed companies to pressure-test frameworks for causal human biology as the north star for AI-driven drug discovery
- fundraisingAn angel syndicate dinner with bio-focused investors from Andreessen Horowitz Bio, BoxGroup, and First Round Capital to explore making your first angel checks into AI-driven drug discovery startups where your translational medicine expertise creates real diligence edge
- tacticalA dinner with founders and dealmakers behind asset-light NewCo spinouts — including alumni of the BMS–Bain Capital immunology model, Pfizer Ventures deals, and Flagship's company creation engine — to map replicable playbooks for spinning out BMS pipeline assets
- introsAn intimate dinner with early-stage Series A biotech CEOs backed by Atlas Venture, Foresite Capital, and OrbiMed to explore formal scientific advisory board and board observer roles where your translational medicine credibility converts directly into equity-aligned influence
- positioningA happy hour with biopharma thought leaders who've successfully scaled newsletters and podcasts — including founders of Timmerman Report, The Long Run, and Endpoints News — to map a concrete editorial and distribution strategy for turning Plenge Gen into a structured weekly newsletter or podcast
- positioningA pre-conference dinner with program chairs and past keynote speakers from JPM Healthcare, STAT Summit, and BIO International to workshop a signature AI-in-drug-discovery talk that positions you as the go-to scientific voice on causal biology meets machine learning
- wellbeingA half-day roundtable with CROs and research heads from Roche, Novartis, and AstraZeneca who lead comparably scaled global research organizations to share structured delegation frameworks and leadership development playbooks for sustaining impact across 10+ site operations
- introsA small-group office hours session with 4-6 pre-seed and seed-stage AI-bio founders from the Petri, YC Bio, and IndieBio cohorts where you stress-test their target identification and translational medicine assumptions in exchange for early advisory equity conversations